Overview of Dr. Seward
Dr. Shelly Seward is an obstetrician/gynecologist in Orlando, FL and is affiliated with multiple hospitals in the area, including Orlando Health Orlando Regional Medical Center, Orlando Health - Health Central Hospital, Orlando Health St. Cloud Hospital, Oviedo Medical Center, and AdventHealth Orlando. She received her medical degree from Eastern Virginia Medical School and has been in practice 13 years. Dr. Seward accepts several types of health insurance, listed below. She is one of 13 doctors at Oviedo Medical Center and one of 270 doctors at AdventHealth Orlando who specialize in Obstetrics & Gynecology. She has more than 20 publications and over 500 citings.
Office
3438 Lawton Rd, Suite 2D
Orlando, FL 32803Fax+1 407-904-0410
Education & Training
- Detroit Medical Center/Wayne State UniversityFellowship, Gynecologic Oncology, 2008 - 2012
- Ohio State University/Mt Carmel HospitalResidency, Obstetrics and Gynecology, 2004 - 2008
- Eastern Virginia Medical SchoolClass of 2004
Certifications & Licensure
- MI State Medical License 2008 - 2027
- FL State Medical License 2018 - 2026
- OH State Medical License 2004 - 2008
- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Clinical Trials
- First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors Start of enrollment: 2012 Jun 28
- A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer Start of enrollment: 2013 Nov 01
Publications & Presentations
PubMed
- 28 citationsRestoration of E-cadherin expression in pancreatic ductal adenocarcinoma treated with microRNA-101Aamer Qazi, Oksana V. Gruzdyn, Assaad Semaan, Shelly Seward, Sreedhar Chamala
Surgery. 2012-10-01 - 88 citationsPhase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.Kathleen N. Moore, Hossein Borghaei, David M. O'Malley, Woondong Jeong, Shelly Seward
Cancer. 2017-08-15 - 16 citationsTherapy-related myeloid leukemia after treatment for epithelial ovarian carcinoma: an epidemiological analysis.Agnieszka Vay, Sanjeev Kumar, Shelly Seward, Assaad Semaan, Charles A. Schiffer
Gynecologic Oncology. 2011-12-01
Press Mentions
- Healthcare Professionals & ResearchJanuary 11th, 2017
- Karmanos Cancer InstituteJanuary 11th, 2017
Professional Memberships
- Fellow
Insurance Accepted
- Aetna Choice POS II
BCBS Blue Card PPO
BCBS Illinois PPO
CIGNA Open Access
CIGNA PPO
Great West PPO
Lifewise Health Plan of OregonMultiplan PHCS PPO
ODS Network
PriorityHealth HMO
Providence Health System Personal Option
Providence Health System Preferred PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: